At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 736 enrolled
Drug / intervention
Certolizumab Pegol (CZP)biological
Likely dose
Certolizumab Pegol (CZP) 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 4, Randomized, 52-Week Study To Evaluate Two Assessment Tools To Predict Treatment Success At 52 Weeks Based On A Treatment Decision At Week 12 In Subjects With Moderate To Severe Rheumatoid Arthritis Receiving Cimzia
In Brief
A Phase 4 clinical trial evaluating Certolizumab Pegol (CZP) for Rheumatoid Arthritis. Completed, enrolled 736 participants across 110 sites.
Detailed Summary
Phase 4 study to evaluate a routine patient completed assessment (RAPID3) compared to a physician completed assessment (CDAI) to predict treatment success with subjects with moderate to severe rheumatoid arthritis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2010
First PostedDec 2010
Primary CompletionOct 2012
Study CompletionDec 2012
TodayJul 2026
First PostedDec 7, 2010
Enrollment StartNov 1, 2010
Primary CompletionOct 1, 2012
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 15.6 years ago
Interventions
Certolizumab Pegol (CZP)biological
400 mg subcutaneous injection at Weeks 0, 2 and 4 200 mg subcutaneous injection every two weeks, Week 6 through Week 52